Pfizer faces a $1 billion sales hit in 2025 from IRA reforms, flat EPS and revenue forecasts, and long-term risks tied to patent expirations.

Why Pfizer stock fell. Pfizer stock fell about 8% when the market opened on Dec. 13 in a knee-jerk reaction to forward-looking estimates that didn't align with Wall Street's predictions.

The average 12-month price target of 13 analysts is $45.46. The price target of the 5 analysts that rated the stock since the last quarterly report is $47.80. Pfizer has a P/E of 14.11x, and a ...

On Jan. 28, Citigroup Inc analyst Geoff Meacham reduced Pfizer's price target from $30 to $29 while maintaining a “Neutral” rating on the stock. The mean price target of $31.29 represents a ...

Pfizer Lifts Outlook as Company Seeks ... to significantly change the narrative on the stock, which we see as more likely in 2025 or beyond,” JPMorgan analyst Chris Schott wrote ...

Two weeks ago Pfizer/BioNTech submitted an Emergency Use Application (EUA) to the FDA for a second booster dose. See what this means for PFE stock's outlook.

The analyst anticipates that Pfizer’s management will guide to EPS in the mid-to-high $2 range with core business growth offset by the $0.30 in favorable but non-recurring items during 2024.

Pharmaceutical giant Pfizer PFE beat earnings expectations and lifted its guidance this week, but analysts at Mizuho Securities downgraded the stock to neutral from buy on Thursday, maintaining ...